Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
75 hedge funds and large institutions have $12.6M invested in Oncternal Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 22 reducing their positions, and 23 closing their positions.
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
4% less funds holding
Funds holding: 78 → 75 (-3)
20% less call options, than puts
Call options by funds: $92K | Put options by funds: $115K
23% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 22
32% less capital invested
Capital invested by funds: $18.6M → $12.6M (-$5.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.09M |
| 2 |
Millennium Management
New York
|
+$943K |
| 3 |
BC
BIT Capital
Berlin,
Germany
|
+$465K |
| 4 |
E
Ergoteles
New York
|
+$238K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.35M |
| 2 |
State Street
Boston,
Massachusetts
|
-$734K |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$585K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$454K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$346K |
ONCT Hedge Fund Activity: Q2 2022 in Review
75 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2022, worth a combined $12.6M — down 32% from $18.6M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ONCT and 21 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 17 added.
The largest buyer was Citadel Advisors, adding an estimated $1.09M. The largest seller was BlackRock, cutting an estimated $2.35M.
- 75 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2022, down from 78 in Q1 2022.
- Funds reported $12.6M of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2022, down 32% quarter-over-quarter.
- 21 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2022 and 23 closed out, a net change of -2 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2022 was Citadel Advisors, an estimated $1.09M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $2.35M sold.
Based on aggregated 13F filings for Q2 2022.